Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell

Kyung-Ok Kim1, Woo-Jae Park2,3, YunJae Jung3,4

  • 1Gachon Medical Research Institute, Gil Medical Center, Gachon University, Incheon, Korea.

Insights

Microsatellite instability (MSI) status impacts MEK or BRAF inhibitor effectiveness in KRAS-mutated colon cancer. Combination therapy shows synergistic effects, inhibiting proliferation regardless of MSI status.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • KRAS-mutated colorectal cancer (CRC) presents therapeutic challenges.
  • Distinct microsatellite instability (MSI) statuses (MSI-high/MSI-H and microsatellite stable/MSS) influence treatment response.
  • Targeting MEK and BRAF pathways is a strategy for CRC treatment.

Purpose of the Study:

  • To investigate the differential responsiveness of KRAS-mutated CRC cell lines with varying MSI statuses to MEK and BRAF inhibitors.
  • To evaluate the synergistic potential of combining MEK and BRAF inhibitors in KRAS-mutated CRC.
  • To determine if MSI status affects the efficacy of single-agent or combination therapy.

Main Methods:

  • Utilized KRAS-mutated CRC cell lines with distinct MSI statuses (LS174T - MSI-H, SW480 - MSS).
  • Assessed cell viability upon treatment with MEK inhibitor (selumetinib; AZD) and/or BRAF inhibitor (vemurafenib; PLX).
  • Measured extracellular signal-regulated kinase (ERK) phosphorylation to confirm pathway inhibition.

Main Results:

  • MSI-H KRAS-mutated cells showed higher sensitivity to MEK inhibition (AZD) compared to BRAF inhibition (PLX).
  • MSS KRAS-mutated cells exhibited greater sensitivity to BRAF inhibition (PLX) than MEK inhibition (AZD).
  • Combination therapy (AZD/PLX) synergistically inhibited proliferation in both MSI-H and MSS KRAS-mutated cells, evidenced by reduced ERK phosphorylation.

Conclusions:

  • MSI status is a critical factor influencing the efficacy of individual MEK or BRAF inhibitors in KRAS-mutated CRC.
  • Combined MEK and BRAF inhibition offers a synergistic therapeutic strategy for KRAS-mutated CRC, irrespective of MSI status.
  • Consideration of MSI status is recommended for personalized treatment selection with MEK/BRAF inhibitors in KRAS-mutated CRC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K